Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-α, IL-1β and IL-1Ra

Inflammation Research

Volumn 56, Issue 6, 2007, Pages 230-239

  Sandler, C ^a   Lindstedt, K A ^b   Joutsiniemi, S ^a   Lappalainen, J ^b   Juutilainen, T ^a   Kolah, J ^a   Kovanen, P T ^b   Eklund, K K ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b WIHURI RESEARCH INSTITUTE   (Finland)

Author keywords

Cytokine; Mast cell; Rheumatoid arthritis

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MALE; MAST CELL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIUM; TISSUE DISTRIBUTION;

AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARTHRITIS, RHEUMATOID; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN E; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; KNEE; MALE; MAST CELLS; MIDDLE AGED; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34347378283     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-007-6135-1     Document Type: Article

References (26)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
2. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-96.
3. Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology 2004; Suppl 3: 2-9.
4. Gordon JR, Galli S. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 1990; 346: 274-6.
5. Tetlow LC, Woolley DE. Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies. Ann Rheum Dis 1995; 54: 896-903.
6. Gotis-Graham I, McNeil HP. Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression. Arthritis Rheum 1997; 40: 479-89.
7. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002; 297: 1689-92.
8. Nigrovic PA, Lee DM. Mast cells in inflammatory arthritis. Arthritis Res Ther 2005; 7: 1-11.
9. Woolley DE. The mast cell in inflammatory arthritis. N Engl J Med 2003; 348: 1709-11.
10. Juurikivi A, Sandler C, Lindstedt KA, Kovanen PT, Juutilainen T, Leskinen M et al. Inhibition of c-Kit tyrosine kinase with imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia; a potential approach for treatment of arthritis. Ann Rheum Dis 2005; 64: 1126-31.
11. Eklund KK, Joensuu H. Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Ann Med 2003; 35: 362-7.
12. Miyachi K, Ihara A, Hankins RW, Murai R, Meahiro S, Miyashita H. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 2003; 22: 329-32.
13. Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci USA 1986; 83: 8749-53.
14. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin-1 receptor antagonist-deficient mice. J Exp Med 2000; 191: 313-20.
15. Malyak M, Swaney RE, Arend WP. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils. Arthritis Rheum 1993; 36: 781-9.
16. Dinarello CA. The role of interleukin-1- receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000; 343: 732-4.
17. Woolley DE, Tetlow LC. Mast cell activation and its relation to pro-inflammatory cytokine production in the rheumatoid lesion. Arthritis Res 2000; 2: 65-74.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
19. t). Methods 2001; 25: 402-8.
20. Okamoto H, Nakano K Regulation of interleukin-1 synthesis by histamine produced by mouse peritoneal macrophages per se Immunology 1990; 69: 162-5.
21. Triggiani M, Gentile M, Secondo A, Granata F, Oriente A, Taglialatela M et al. Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors.. J Immunol. 2001; 166: 4083-91.
22. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin1 receptor antagonist. J Clin Invest 1990; 85: 1694-7.
23. Gruber B, Ballan D, Gorevic PD. IgE rheumatoid factors: quantification in synovial fluid and ability to induce synovial mast cell histamine release. Clin Exp Immunol 1988; 71: 289-94.
24. Kiener HP, Baghestanian M, Dominkus M, Walchshofer S, Ghannadan M, Willheim M et al. Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 233-45.
25. Eklund KK, Joensuu H. Treatment of rheumatoid arthritis with Imatinib mesylate: Clinical improvement in three refractory cases. Ann Med 2003; 35: 362-7.
26. Miyachi, K, A. Ihara, R.W. Hankins, R. Murai, S. Maehiro, H. Miyashita. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 2003; 22: 329-32.